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The reaction of the hydroiodide of S-methyl isothiosemicarbazide (1), prepared from 
thiosemicarbazide by treatment with MeI in EtOH, and aryl isoselenocyanates 5 in CH2Cl2 
affords 1,2,4-triazole-3-selone derivatives 7 in good yield. During attempted crystallization, 
these products undergo an oxidative dimerization to give the corresponding bis(4H-1,2,4-
triazol-3-yl)diselenides 11. The structure of 11a has been established by X-ray 
crystallography. 
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1. Introduction. – The biochemistry and pharmacology of selenium is of current 
interest, particularly with regard to public health. Selenium has long been recognized as a 
dietary antioxidant and is now known to be an essential component to the active sites of 
several enzymes, including glutathione peroxidase [1] and thioredoxine reductase, which 
catalyze reactions essential for the protection of cellular components against oxidative and 
free radical damage [2]. A too low concentration of selenium in the plasma has been 
identified as a risk factor for several diseases, including cancer [3], cardiovascular disease [4], 
osteoarthritis or AIDS [5]. Therefore, consumption of Se-rich plants or yeast-based nutritional 
supplements is reported to reduce the risk of cancer. It has also been suggested that plants are 
able to convert inorganic Se in the soil or growth medium into organoselenium compounds, 
such as selenoamino acids [6], by following a route similar to the sulfur assimilatory pathway 
[7].  
 
In recent years, the interest in organoselenium chemistry increased remarkably. 
There is no doubt that Se-containing organic molecules have played and continue to play an 
important role in biology and medicine, and a large number of them are now accepted as 
useful antioxidants [8], anticancer [9] and melanin synthesis regulating agents [10], 
superoxide anion-scavengers [11], anti-inflammatory agents [12], and compounds with 
antihypertensive [13], antinociceptive [14], antibiotic [15], and antiviral activity [16], i.e., 
organoselenium compounds are nowadays an important class of biologically active products 
[17] with pharmaceutical applications [18]. 
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The interest in Se compounds may also be attributed to their specific chemical 
properties, which fit well into the requirements of modern organic synthesis, and many of 
them are well adapted to chemo-, regio- and stereoselective reactions [19][20].  
 
For all of these reasons, isoselenocyanates became a focus of interest in our research 
group as building blocks in the synthesis of Se-containing heterocycles. Their special 
chemical properties [21] make them very useful starting materials in heterocyclic chemistry 
[22], as they are easy to prepare and safe to store [23]. Nevertheless, under mild conditions, 
they undergo reactions, which are compatible with the presence of a variety of unsaturated as 
well as multi-functional structural units. Therefore, they are useful reagents in the preparation 
of natural products [24]. 
  
Within the family of triazoles, the corresponding thiones have gained especial 
importance. Several examples were described to be of pharmaceutical interest, e.g., as agents 
with antibacterial activity [25]. A series of 1,2,4-triazolethiones have been prepared by using 
isothiocyanates [25–27] (and refs. cited therein). For example, 3,4-dihydro-2H-1,2,4-triazole-
3-thione derivatives were synthesized by the reaction of isothiocyanates with amidrazone 
hydrochlorides [26]. Correspondingly, 5-amino derivatives were obtained when S-methyl 
isothiosemicarbazide hydroiodide (1) [28] was reacted with primary aryl- or benzylamines, 
and the resulting guanidinium iodide 2 was subsequently treated with aryl isothiocyanates in 
EtOH [25b] (Scheme 1). Depending on the reaction temperature, 5-arylamino- (3) or 5-amino-
1,2,4-triazole-3-thiones (4) were isolated. 
 
Scheme 1 
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As for the reaction of isoselenocyanates with nucleophiles, it is known that N, O, S, and 
Se-nucleophiles add to the central C-atom [21a], whereas P-nucleophiles attack either the 
central C-atom or the Se-atom [21b][29]. However, only a few examples have been reported 
for the reaction of hydrazine derivatives with isoselenocyanates [30] and nothing is known on 
the reaction with guanidine compounds. Very recently, we have published the synthesis of 
1,3,4-selenadiazine derivatives from hydrazine, α-bromoacetophenones and 
isoselenocyanates [31]. 
 
As a continuation of the previously published studies on the synthesis of Se-containing 
heterocycles based on isoselenocyanate chemistry [32], we have recently reported on the 
synthesis of 5-selenoxo-1,2,4-triazole-1-carboxylates by using a Mitsunobu strategy [33]. 
Following a similar strategy, Koketsu et al. have published the preparation of 3-selenoxo-
1,2,4-triazole derivatives by the reaction of acyl isoselenocyanates with phenyl hydrazine 
[30]. Furthermore, reactions of isoselenocyanates 5 with mercapto acids led to 2-selenoxo-
1,3-thiazolidin-4-ones and 2-selenoxo-1,3-thiazinan-4-ones in good yields [34].  
 
In the present paper, the results of the investigations aimed at extending this 
methodology to the synthesis of 5-amino-1,2,4-triazole-3-selone derivatives are reported. 
 
2. Results and Discussion. – In the synthesis of the 1,3,4-selenadiazine derivatives [31], 
hydrazine was used as a bisnucleophilic reagent, which combined first with the aryl 
isoselenocyanate 5 and, in a later reaction step, underwent the cyclization with the 
acetophenone residue of the intermediate. In this case, cyclization occurred via a condensation 
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reaction. We report here the use of S-methyl thiosemicarbazide (1) bearing a methylthio 
group, which will be the leaving group in the cyclization step of the preparation of 5-amino-4-
aryl-2H-1,2,4-triazole-3-selones 7 according to Scheme 2. After stirring for 12 h, the products 
were separated by filtration; they were obtained in good yields and were pure enough to give 
unambiguous spectroscopic data and elemental analyses (Table 1). 
 
Scheme 2 
 
Table 1 
 
The structures of compounds 7 were established on the basis of their spectroscopic data, 
which correspond reasonably well with those of the previously described 5-selenoxo-1,2,4-
triazole-1-carboxylates [33]. In the IR-spectra (KBr), the triazoleselones 5 show weak 
absorptions for NH at 3380–3150 cm–1 and a strong C=N absorption at ca. 1640 cm–1. The 
1H-NMR signals for the NH and NH2 groups in CDCl3 appear at 13.6–12.9 and 6.5–5.3 ppm, 
respectively. Characteristic signals in the 13C-NMR spectra are observed for the triazole C-
atoms (C(5) and C(3)) at 152–159 ppm. Furthermore, the ESI-MS show the [M+Na]+ signal 
as the characteristic ensemble of the peaks for the Se isotopes. 
 
A reaction mechanism for the formation of 7 is proposed in Scheme 2. After 
deprotonation of the hydroiodide 1, nucleophilic addition of S-methyl isothiosemicarbazide 
onto 5 leads to an intermediate 6, which undergoes a cyclization via elimination of MeSH. 
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Although all analytical data are in accordance with structure 7, we cannot exclude the 
tautomeric structures 8 and 9 with certainty. Even structure 10, which could be the result of 
the alternative cyclization of 6 via the Se-atom, is compatible with the data. Therefore, we 
decided to prove the structure by X-ray crystallography. However, the triazoles 7, which were 
obtained directly from the reaction mixture after filtration, were always amorphous, and the 
crystallization of these products proved to be a difficult task. An explanation for this behavior 
could be the presence of NH groups with the possibility of the formation of different 
tautomeric structures (i.e. 7–9). The recrystallization needed rather polar solvents, and the 
formation of metallic Se and decomposition of the product was observed even at low 
temperature. After several attempts, crystallization of 7a from MeOH/CH2Cl2 gave orange 
crystals with a m.p. 206–208° and a molecular weight of 478 (ESI-MS). Therefore, the 
structure of the recrystallized product was proposed to be the diselenide 11a, which could be 
formed from the tautomeric triazoleselenol 9a by oxidative dimerization (Scheme 3). This 
assumption was proven by an X-ray crystal-structure determination (Fig. 1). 
 
Scheme 2 
 
Figure 1.  ORTEP Plot [35] of the molecular structure of 11a (arbitrary numbering of 
atoms; 50% probability ellipsoids) 
 
The asymmetric unit in the crystal structure contains one molecule of 11a, one MeOH 
molecule and two molecules of H2O (Fig. 2). The five-membered heterocyclic rings are 
planar, with the adjacent atoms N(3), Se(1) and N(14), C(17), respectively, also being in the 
corresponding plane, while C(6) and Se(2) deviate by 0.213(2) and 0.114(1) Å, respectively, 
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from these planes. The torsion angle C(1)–Se(1)–Se(2)–C(12) is –96.08(9)°, as usually 
observed for oligosulfanes and di- and triselenides (see, e.g., [36][37]). The planes of the Ph 
groups at N(2) and N(13) are significantly twisted out of the planes of their parent 
heterocyclic rings with the dihedral angles between the planes being 87.95(11) and 
55.67(11)°, respectively. 
 
Figure 2.  The molecular packing of 11a projected down the a-axis showing the H-
bonding scheme (equivalent isotropic spheres for atoms; uninvolved H-
atoms omitted for clarity) 
 
Intermolecular H-bonds link the molecules of 11a, MeOH and H2O into a three-
dimensional framework. Each molecule of 11a donates H-bonds to one neighboring molecule 
of 11, as well as to three different H2O molecules. One of the two symmetry-independent H2O 
molecules donates H-bonds to two different molecules of 11a. The other H2O molecule 
donates one H-bond to a molecule of 11a and a second H-bond to the O-atom of a MeOH 
molecule. The MeOH molecule donates a H-bond to one of the H2O molecules. The H-bond 
acceptor atoms in 11a are the unsubstituted N-atoms in the five-membered rings. 
 
In conclusion, we have shown that isoselenocyanates 5 react with isothiosemicarbazide 
hydroiodide 1 in basic media to give an intermediate, which undergoes a ring formation to 
give 4-aryl-3,4-dihydro-2H-1,2,4-triazole-5-selones 7 in good yields. These products are 
easily oxidized to give bis(triazol-3-yl)diselenides 11. 
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Experimental Part 
 
1. General. See [32e][32f]. TLC: silica gel 60 F254 plates (0.25 mm; Merck). Column 
chromatography (CC): silica gel 60 (0.040-0.063 mesh; Merck). M.p.: Büchi B-540 apparatus 
in capillaries; uncorrected. 1H-NMR (300 MHz) and 13C-NMR (75.5 MHz) spectra: Bruker 
ARX-300 instrument, in (D6)DMSO unless otherwise specified; chemical shifts in ppm. ESI-
MS: Finnigan MAT TSQ-700 instrument. 
2. Starting Materials. Isoselenocyanates were prepared according to Barton’s procedure 
starting from formamides [23]. Formanilide is commercially available (Fluka), N-(4-
bromophenyl)-, N-(4-chlorophenyl)-, N-(4-methylphenyl)-, and N-(4-methoxyphenyl)-
formamide were prepared from the respective commercial anilines and 95% HCOOH [38]. 
The soln. was heated to reflux for 30 min and evaporated to dryness in vacuo. The residue 
was dissolved in Et2O and washed with diluted AcOH (5%), H2O and aq. NaHCO3 (5%). The 
aq. phase was extracted with Et2O, the combined org. extracts were dried (MgSO4) and 
evaporated i.v. The crude products were purified by recrystallization in H2O. S-
Methylisothiosemicarbazide hydroiodide (1) was prepared by treatment of thiosemicarbazide 
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(9.10 g, 0.10 mol) with MeI (14.20 g, 0.10 mol) in refluxing abs. EtOH for 2 h. The mixture 
was allowed to cool, and filtration and purification by recrystallization in abs. EtOH yielded 
18.71 g (80%) of 1. M.p. = 137–139° ([39]: 138°). 1H-NMR: 2.69 (s, Me). 13C-NMR: 12.7 
(Me); 170.2 (C). ESI-MS: 234 (2, [M+1]+), 106 (100, C2H8N3S+), 92 (53). Anal. calc. for 
C2H8N3SI (233.07): C 10.31, H 3.46, N 18.03, S 13.76; found: C 10.30, H 3.44, N 18.24, S 
13.59. 
 
3. General Procedure for the Preparation of 1,2,4-Triazole-3-selones 7. A 25 ml round-
bottom flask equipped with a magnetic stirrer and a condenser was charged with a soln. of 1 
(233 mg, 1.0 mmol) and the respective isoselenocyanate 5 (1.0 mmol) in CH2Cl2 (20 ml). 
Then, Et3N (0.28 ml, 2.0 mmol) was added, whereby the suspension became instantaneously 
colorless and then rapidly yellow. The evolution of a gas (methanethiol) was detected. The 
mixture was stirred overnight, then, the white precipitate was filtered and washed with cold 
CH2Cl2 to give analytically pure product. 
 
5-Amino-3,4-dihydro-4-phenyl-2H-1,2,4-triazole-3-selone (7a). From phenylisoseleno-
cyanate (5a). Yield: 187 mg (78%). White crystals. M.p. 191–193° (CH2Cl2). IR (KBr): 
3363w, 3287w, 3249w, 3158m (br), 2970w, 2936w, 2785w, 1640s, 1593m, 1496s, 1450m, 
1336m, 1237m, 1139w, 1071w, 1011w, 991w, 784w, 749m, 690s, 567m. 1H-NMR: 5.94 (br. s, 
NH2); 7.25 (d, J = 8.1, 2 arom. H); 7.42–7.49 (m, 3 arom. H); 13.57 (br. s, NH). 13C-NMR: 
128.4 (2 arom. CH); 129.2 (3 arom. CH); 133.3 (1 arom. C); 153.1 (C(5)); 155.8 (C=Se). ESI-
MS: 265 (12), 264 (10), 263 (100, [M+Na]+), 262 (5), 261 (47), 260 (14), 259 (13). Anal. 
calc. for C8H8N4Se (239.14): C 40.18, H 3.37, N 23.43; found: C 39.93, H 3.49, N 23.20. 
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5-Amino-3,4-dihydro-4-(4-methoxyphenyl)-2H-1,2,4-triazole-3-selone (7b). From (4-
methoxyphenyl)isoselenocyanate (5b). Yield: 194 mg (72%). White crystals. M.p. 177–179° 
(CH2Cl2). IR (KBr): 3373w, 3307w, 3261w, 3200w, 3158w, 2999w, 2935w, 2808w, 1646s, 
1604w, 1583w, 1513s, 1459m, 1442m, 1338m, 1302m, 1259s, 1240m, 1184w, 1170m, 1130m, 
1103w, 1048w, 1021w, 1007w, 989w, 833m, 803w, 768w, 728w, 665w, 629w, 619w, 573w. 
1H-NMR: 4.06 (s, MeO); 6.25 (br. s, NH2); 7.31, 7.49 (AA’BB’, J = 8.1, 4 arom. H); 13.52 
(br. s, NH). 13C-NMR: 55.3 (MeO); 114.4 (2 arom. CH); 125.8 (1 arom. C); 129.7 (2 arom. 
CH); 153.3 (1 arom. C); 156.1 (C(5)); 159.5 (C=Se). ESI-MS: 295 (12), 294 (11), 293 (100, 
[M+Na]+), 292 (9), 291 (45), 290 (16), 289 (18). Anal. calc. for C9H10N4OSe (269.17): C 
40.16, H 3.74, N 20.82; found: C 40.31, H 3.40, N 21.06. 
 
5-Amino-3,4-dihydro-4-(4-methylphenyl)-2H-1,2,4-triazole3-selone (7c). From (4-
methylphenyl)isoselenocyanate (5c). Yield: 203 mg (80%). White crystals. M.p. 182–184° 
(CH2Cl2). IR (KBr): 3367w, 3298w, 3255w, 3159w, 2999w, 2942w, 2798w, 1645s, 1599w, 
1578w, 1500s, 1465m, 1443m, 1332m, 1295m, 1245m, 1240m, 1178w, 1165m, 1128m, 
1105w, 1055w, 1018w, 1000w, 978w, 835w, 798w, 777w, 725w, 656w. 1H-NMR: 2.42 (s, 
Me); 5.28 (br. s, NH2); 7.26, 7.30 (AA’BB’, J = 8.1, 4 arom. H); 12.91 (br. s, NH). 13C-NMR: 
20.6 (Me); 127.1 (2 arom. CH); 129.7 (1 arom. C); 129.8 (2 arom. CH); 139.3 (1 arom. C); 
156.1 (C(5), C=Se). ESI-MS: 279 (12), 278 (12), 277 (100, [M+Na]+), 276 (7), 275 (55), 274 
(12), 273 (17). Anal. calc. for C9H10N4Se (253.17): C 42.70, H 3.98, N 22.13; found: C 42.56, 
H 4.12, N 22.23. 
 
5-Amino-4-(4-bromophenyl)-3,4-dihydro-2H-1,2,4-triazole-3-selone (7d). From (4-
bromophenyl)isoselenocyanate (5d). Yield: 261 mg (82%). White crystals. M.p. 192–194° 
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(CH2Cl2). IR (KBr): 3383w, 3294w, 3080m (br), 2927w, 2774w, 1633s, 1586m, 1573m, 
1489m, 1450m, 1403w, 1330m, 1226m, 1103w, 1069w, 1005m, 985w, 835m, 820w, 771w, 
741w, 715w, 570m. 1H-NMR: 6.46 (br. s, NH2); 7.63, 8.05 (AA’BB’, J = 8.1, 4 arom. H); 
13.42 (br. s, NH). 13C-NMR: 122.5 (1 arom. C); 130.8 (2 arom. CH); 132.2 (2 arom. CH); 
139.4 (1 arom. C); 152.9 (C(5)); 155.8 (C=Se). ESI-MS: 345 (13), 344 (8), 343 (78), 342 
(11), 341 (100, [M+Na]+), 340 (16), 339 (48), 338 (15), 337 (12). Anal. calc. for C8H7BrN4Se 
(318.04): C 30.21, H 2.22, N 17.62; found: C 30.36, H 2.55, N 17.63. 
 
5-Amino-4-(4-chlorophenyl)-3,4-dihydro-2H-1,2,4-triazole-3-selone (7e). From (4-
chlorophenyl)isoselenocyanate (5e). Yield: 205 mg (75%). White crystals. M.p. 185–187° 
(CH2Cl2). IR (KBr): 3379w, 3294w, 3084m (br), 2958m, 2931m, 2778w, 1634s, 1587m, 
1574m, 1493s, 1453m, 1409w, 1331m, 1230m, 1106w, 1091w, 1007m, 986w, 840m, 822w, 
774w, 734w, 717w, 574m. 1H-NMR: 6.33 (br. s, NH2); 7.58, 7.79 (AA’BB’, J = 8.7, 4 arom. 
H); 13.47 (br. s, NH). 13C-NMR: 129.3 (2 arom. CH); 130.5 (2 arom. CH); 132.2 (1 arom. C); 
133.9 (1 arom. C); 153.0 (C(5)); 155.8 (C=Se). CI-MS (NH3): 277 (3), 275 (7, [M+1]+), 273 
(4), 197 (34), 196 (12), 195 (100), 194 (6). Anal. calc. for C8H7ClN4Se (273.59): C 35.12, H 
2.58, N 20.48; found: C 34.90, H 2.80, N 20.34. 
 
Bis(5-amino-4-phenyl-1,2,4-triazol-3-yl)diselenide (11a). Repeated attempts to 
crystallize 7a from CH2Cl2 gave orange crystals of 11a. M.p. 206.0–208.3° (color change). 
1H-NMR: 6.05 (br. s, 2 NH2); 6.97 (d-like, 4 arom. H); 7.42–7.50 (m, 6 arom. H). ESI-MS: 
504 (9), 503 (29), 502 (20), 501 (100, [M+Na]+), 500 (21), 499 (77), 498 (31), 497 (43), 496 
(13), 495 (17), 479 (19, [M+1]+), 477 (17). 
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X-Ray Crystal-Structure Determination of 11a (see Fig. 1 and Table 2)3). All 
measurements were made on a Nonius KappaCCD diffractometer [40] using graphite-
monochromated MoKα radiation (λ 0.71073 Å) and an Oxford Cryosystems Cryostream 700 
cooler. Data reduction was performed with HKL Denzo and Scalepack [41]. The intensities 
were corrected for Lorentz and polarization effects, and an absorption correction based on the 
multi-scan method [42] was applied. Equivalent reflections were merged. Data collection and 
refinement parameters are given in Table 2, and a view of the molecule is shown in the 
Figure. The structure was solved by direct methods using SHELXS97 [43], which revealed the 
positions of all non-H-atoms. The asymmetric unit contains one molecule of the Se-
compound, one MeOH molecule and two molecules of H2O. The non-H-atoms were refined 
anisotropically. The NH2, H2O and hydroxy H-atoms were placed in the positions indicated 
by a difference electron density map and their positions were allowed to refine together with 
individual isotropic displacement parameters. All remaining H-atoms were placed in 
geometrically calculated positions and refined using a riding model where each H-atom was 
assigned a fixed isotropic displacement parameter with a value equal to 1.2Ueq of its parent C-
atom (1.5 Ueq for the Me group of the MeOH molecule). Refinement of the structure was 
carried out on F2 using full-matrix least-squares procedures, which minimized the function 
Σw(Fo2 – Fc2)2. A correction for secondary extinction was applied. Four reflections, whose 
intensities were considered to be extreme outliers, were omitted from the final refinement. 
Neutral atom scattering factors for non-H-atoms were taken from [44], and the scattering 
factors for H-atoms were taken from [45]. Anomalous dispersion effects were included in Fc 
                                                          
3) CCDC-631597 contains the supplementary crystallographic data for this paper. These data 
can be obtained free of charge from the Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data-request/cif. 
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[46]; the values for ƒ’ and ƒ” were those of [47]. The values of the mass attenuation 
coefficients are those of [48]. All calculations were performed using the SHELXL97 [49] 
program. 
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Table 1. Preparation of 5-Amino-3,4-dihydro-2H-1,2,4-triazole-5-selones 7 from 
Isoselenocyanates 5  
 
Table 2.  Crystallographic Data of Compound 11a 
 
 
Figure 2: The molecular packing of 11a projected down the a-axis showing the H-bonding 
scheme (equivalent isotropic spheres for atoms; uninvolved H-atoms omitted for clarity) 
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Table 1: Preparation of 5-Amino3,4-dihydro-2H-1,2,4-triazole-5-selones 7 from 
Isoselenocyanates 5  
 
Entry R1 7 Yield (%) 
 
a 
 
Ph 
NHN
N SeH2N
 
 
78 
 
b 
 
4-MeO-C6H4 
NHN
N SeH2N
OCH3  
 
72 
 
c 
 
4-Me-C6H4 
NHN
N SeH2N
CH3  
 
80 
 
d 
 
4-Br-C6H4 
NHN
N SeH2N
Br  
 
82 
 
 
 
 
e 
 
4-Cl-C6H4 
NHN
N SeH2N
Br  
 
75 
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Table 2.  Crystallographic Data of Compound 11a 
Crystallized from  CH2Cl2/MeOH 
Empirical formula  C17H22N8O3Se2 
Formula weight [g mol–1]  544.33 
Crystal color, habit  orange, tablet 
Crystal dimensions [mm]  0.10 × 0.22 × 0.28 
Temperature [K]  160(1) 
Crystal system  monoclinic 
Space group  P21/n 
Z  4 
Reflections for cell determination 65007 
2θ range for cell determination [°] 4–60 
Unit cell parameters a [Å]  8.6743(1)  
  b [Å]  14.3351(1) 
  c [Å]  17.8878(2) 
  β [°]  102.8824(6) 
  V [Å3]  2168.31(4) 
Dx [g cm–3]  1.667 
µ(MoKα) [mm–1]  3.447 
Scan type  φ and ω 
2θ(max) [°]  60 
Transmission factors (min; max)  0.492; 0.717 
Total reflections measured  55961 
Symmetry independent reflections 6352 
Reflections with I > 2σ (I)  5010 
Reflections used in refinement  6348 
Parameters refined  309 
Final  R(F) [I > 2σ (I) reflections] 0.0340 
 wR(F2) (all data)   0.0841 
Weights: w = [σ 2 (Fo2) + (0.0433P)2 + 0.7378P]–1 where P = (Fo2 + 2Fc2)/3 
23 
Goodness of fit  1.034 
Secondary extinction coefficient  0.0010(3) 
Final ∆max/σ  0.001 
∆ρ (max; min) [e Å–3]  0.62; –0.91 
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Scheme 2 
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Scheme 3 
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Figure 1. ORTEP Plot [48] of the molecular structure of 11a (arbitrary numbering of 
atoms; 50% probability ellipsoids) 
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Figure 2: The molecular packing of 11a projected down the a-axis showing the H-bonding 
scheme (equivalent isotropic spheres for atoms; uninvolved H-atoms omitted for clarity) 
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